NCT00156949View on ClinicalTrials.gov

EPO Deep Tank in Dialysis Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

580

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Chronic Kidney Disease
Interventions
DRUG

Epoetin alfa DT

Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY